NCT03414814 2025-02-11
Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation
Seoul National University Hospital
Phase 2 Completed
Clinical Trials
6 trialsNCT03433469 2025-01-31
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
University of California, San Francisco
Phase 2 Active not recruiting
NCT02841579 2025-01-28
AZENT
MedSIR
Phase 2 Completed
NCT02954523 2024-07-05
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Georgetown University
Phase 1/2 Terminated
NCT03434418 2023-10-17
A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
Duke University
Phase 2 Completed
NCT02803203 2023-09-22
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed